Literature DB >> 15907369

Protein kinase C (PKC) family in cancer progression.

Jussi Koivunen1, Vesa Aaltonen, Juha Peltonen.   

Abstract

PKC family consist of a number of serine-threonine kinases which are divided into three groups based on their activating factors. PKCs have been linked to carcinogenesis since PKC activators can act as tumor promoters. Furthermore, functional studies have suggested that PKCs play a role in the carcinogenesis and maintenance of malignant phenotype. Potentiation of malignant phenotype may be mediated by activation of selective PKC isoenzymes or through altered isoenzyme expression profile compared to the originating tissue. Activation of PKCalpha and beta isoenzymes have often been linked to malignant phenotype while PKCdelta is thought to mediate anti-cancer effects. This review will focus on the regulation and significance of PKC isoenzymes to cancer progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 15907369     DOI: 10.1016/j.canlet.2005.03.033

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  83 in total

Review 1.  The life and death of protein kinase C.

Authors:  Christine M Gould; Alexandra C Newton
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

Review 2.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

Review 3.  Features of the Phosphatidylinositol Cycle and its Role in Signal Transduction.

Authors:  Richard M Epand
Journal:  J Membr Biol       Date:  2016-06-08       Impact factor: 1.843

4.  Curcumin Inhibits Protein Kinase Cα Activity by Binding to Its C1 Domain.

Authors:  Satyabrata Pany; Youngki You; Joydip Das
Journal:  Biochemistry       Date:  2016-11-02       Impact factor: 3.162

5.  AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.

Authors:  Chenfei Huang; Zhe Cao; Jun Ma; Yi Shen; Yiwen Bu; Ramina Khoshaba; Guiyuan Shi; Dan Huang; Duan-Fang Liao; Haitao Ji; Junfei Jin; Deliang Cao
Journal:  Mol Carcinog       Date:  2018-06-28       Impact factor: 4.784

6.  Differential signaling of the GnRH receptor in pituitary gonadotrope cell lines and prostate cancer cell lines.

Authors:  Ludmila Sviridonov; Masha Dobkin-Bekman; Boris Shterntal; Fiorenza Przedecki; Linor Formishell; Shani Kravchook; Liat Rahamim-Ben Navi; Tali Hana Bar-Lev; Marcelo G Kazanietz; Zhong Yao; Rony Seger; Zvi Naor
Journal:  Mol Cell Endocrinol       Date:  2013-02-01       Impact factor: 4.102

7.  IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Brian A Menegaz; Vandhana Ramamoorthy; Deeksha Vishwamitra; Ying Wang; Rebecca L Maywald; Adriana S Buford; Izabela Fokt; Stanislaw Skora; Jing Wang; Aung Naing; Alexander J Lazar; Eric M Rohren; Najat C Daw; Vivek Subbiah; Robert S Benjamin; Ravin Ratan; Waldemar Priebe; Antonios G Mikos; Hesham M Amin; Joseph A Ludwig
Journal:  J Natl Cancer Inst       Date:  2016-08-30       Impact factor: 13.506

8.  Antisense expression of PKCalpha improved sensitivity of SGC7901/VCR cells to doxorubicin.

Authors:  Da-Long Wu; Feng-Ying Sui; Cheng Du; Cheng-Wen Zhang; Bin Hui; Shui-Ling Xu; Huan-Zhang Lu; Guo-Jie Song
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

9.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

10.  ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.

Authors:  Jing-Shan Tong; Qing-Hua Zhang; Zhen-Bo Wang; Sen Li; Cai-Rong Yang; Xue-Qi Fu; Yi Hou; Zhao-Yi Wang; Jun Sheng; Qing-Yuan Sun
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.